NOX4 and melanoma: Data obtained in SK-MEL-28 cell line are consistent with the one obtained in primary BRAF mutated melanoma cells, thus highlighting that the use of a Nox4 inhibitor could potentiate the current therapeutic strategy to treat melanoma patients with BRAF mutations.